Equity Overview
Price & Market Data
Price: $1.27
Daily Change: +$0.11 / 8.66%
Range: $1.10 - $1.35
Market Cap: $52,177,568
Volume: 9,218
Performance Metrics
1 Week: 12.69%
1 Month: 30.24%
3 Months: -11.19%
6 Months: -18.59%
1 Year: -38.05%
YTD: -24.40%
Company Details
Employees: 3
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas.